Ponatinib

Iclusig (ponatinib) is a small molecule pharmaceutical. Ponatinib was first approved as Iclusig on 2012-12-14. It is used to treat myeloid leukemia in the USA. It has been approved in Europe to treat lymphoid leukemia and myeloid leukemia. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target cyclin-dependent kinase 19, proto-oncogene tyrosine-protein kinase receptor Ret, cyclin-dependent kinase 8, receptor-interacting serine/threonine-protein kinase 3, receptor-interacting serine/threonine-protein kinase 2, and receptor-interacting serine/threonine-protein kinase 1. Iclusig's patents are valid until 2033-12-12 (FDA).